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Abstract: The use of poly-(D,L-lactic-co-glycolic) acid (PLGA) particles as carriers for DNA delivery has 
received considerable attention in mammalian studies. DNA vaccination of fish has been shown to elicit 
durable transgene expression, but no reports exist on intramuscular administration of PLGA-
encapsulated plasmid DNA (pDNA). We injected Atlantic salmon (Salmo salar L.) intramuscularly with 
a plasmid vector containing a luciferase (Photinus pyralis) reporter gene as a) naked pDNA, b) 
encapsulated into PLGA nano- (~320nm) (NP) or microparticles (~4µm) (MP), c) in an oil-based 
formulation, or with empty particles of both sizes. The ability of the different pDNA-treatments to 
induce transgene expression was analyzed through a 70-day experimental period. Anatomical 
distribution patterns and depot effects were determined by tracking isotope labeled pDNA. Muscle, 
head kidney and spleen from all treatment groups were analyzed for proinflammatory cytokines 
(TNFα, IL-1β), antiviral genes (IFN-α, Mx) and cytotoxic T-cell markers (CD8, Eomes) at mRNA 
transcription levels at days 1, 2, 4 and 7. Histopathological examinations were performed on injection-
site samples from days 2, 7 and 30. Injection of either naked pDNA or the oil-formulation was superior 
to particle treatments for inducing transgene expression at early time-points. Empty particles of both 
sizes were able to induce proinflammatory immune responses as well as degenerative and 
inflammatory pathology at the injection site. Microparticles demonstrated injection-site depots and an 
inflammatory pathology comparable to the oil-based formulation. In comparison, the distribution of 
NP-encapsulated pDNA resembled that of naked pDNA, although encapsulation into NPs significantly 
elevated the expression of antiviral genes in all tissues. Together the results indicate that while naked 
pDNA is most efficient for inducing transgene expression, the encapsulation of pDNA into NPs up-






 Plasmid DNA was encapsulated into PLGA nano- and microparticles 
 Naked and encapsulated pDNA was injected into muscle of Atlantic salmon 
 Naked pDNA delivery is superior for inducing transgene expression 
 Nano- and microparticles induce significant expression of inflammatory genes 
 Nanoparticles carrying pDNA significantly up-regulate antiviral genes 
*Highlights (for review)
 
Table 1 – An overview of the preparation protocol and main particle characteristics for pDNA-loaded PLGA nanoparticles 
(NP-(125I-f-pDNA)) and microparticles (MP-(125I-f-pDNA)). (S): preparation by sonication. (H): preparation by 
homogenization. Preparation of empty particles followed the same protocol, but pDNA was excluded from the W1 phase. 
 NP-(125I-f-pDNA) MP-(125I-f-pDNA) 
First water phase (W1) pDNA (3.5 mg) in 600 µl dH2O with 0.1% PVA 
Oil phase (O) 
300 mg PLGA in 6 ml chloroform  
(5% w/v) 
First emulsion (W1/O) S: 30 sec, 35% (262.5 W) S: 35 sec, 30% (225 W) 
Second water phase (W2) 15 ml dH2O with 2% PVA 
Second emulsion (O/W2) S: 1 min, 30% H: 45 sec, 9500 rpm min
-1 
Washing 5000 x g, 15000 x g and 25000 x g 500 x g 
Particle yield (%) 78 89 
Encapsulation efficiency (%) 27 24 
Loading  
(µg pDNA/mg PLGA) 
3.24 2.85 
Mean size 320 nm 3-4 µm 
PLGA injected (mg) 3.5 4 
 
 
Table 2 - Experimental groups and group nomenclature.  
Treatment groups Nomenclature 
(125I-f-pDNA) encapsulated in nanoparticles NP-(125I-f-pDNA) 
(125I-f-pDNA) encapsulated in microparticles MP-(125I-f-pDNA) 
Empty nanoparticles NP 
Empty microparticles MP 
Plasmid DNA in PBS pDNA 
(125I-f-pDNA) in PBS 125I-f-pDNA 
PBS PBS 






Table 3 - Primers for quantitative polymerase chain reaction (QPCR). (*): primers obtained from Natasha Hynes (TNF-α) and 
Jaya Kumari (Eomes). 









































































Table 4 - Histopathological observations in tissue-sections of muscle from the injection site. Muscle degeneration and 
inflammation are classified as either moderate (+) or strong (++), depending on the extent of the pathology. 
Sampling Group Total number of fish Hemorrhage 
Muscle degeneration Inflammation 
+ ++ + ++ 
D2 
NP-(125I-f-pDNA) 3 2 2 0 0 0 
MP-(125I-f-pDNA) 3 2 3 0 2 0 
NP 2 1 1 1 0 0 
MP 3 2 0 2 0 0 
pDNA 3 1 1 2 0 0 
125I-f-pDNA 3 2 0 0 0 0 
PBS 2 1 2 0 0 0 
FIA-(125I-f-pDNA) 1 - 1 - - - 
D7 
NP-(125I-f-pDNA) 3 2 2 0 2 0 
MP-(125I-f-pDNA) 3 0 3 0 2 0 
NP 2 0 1 1 2 0 
MP 2 1 2 0 2 0 
pDNA 3 1 2 0 1 0 
125I-f-pDNA 3 2 1 0 0 0 
PBS 2 0 0 0 0 0 
FIA-(125I-f-pDNA) 1 - - - - - 
D30 
NP-(125I-f-pDNA) 2 0 0 0 2 0 
MP-(125I-f-pDNA) 2 0 1 1 0 2 
pDNA 2 0 0 0 2 0 
125I-f-pDNA 2 0 0 0 0 0 
PBS 1 0 0 0 0 0 















 Please find enclosed a revised manuscript of “Transgene and immune gene 
expression following intramuscular injection of Atlantic salmon (Salmo salar L.) 
with DNA-releasing PLGA nano- and microparticles” by Linn Benjaminsen Hølvold, 
Børge N. Fredriksen, Jarl Bøgwald and Roy A. Dalmo, which we are re-submitting for 
consideration for publication in Fish and Shellfish Immunology. 
 
Our study is the first on intramuscular injection of DNA-releasing PLGA particles 
in Atlantic salmon. We aimed to evaluate the effect that encapsulation of pDNA into 
PLGA nano- and microparticles would have not only on transgene expression, but also on 
immune responses that might modulate the efficacy of the expressed transgene, as well as 
tissue distribution and injection site depots. DNA vaccination has been shown to induce 
protective immune responses in Atlantic salmon, and research on vaccine strategies to 
further improve the efficacy of DNA vaccines should therefore be of interest to the 
readers of Fish and Shellfish Immunology. 
   
The manuscript has been revised in accordance with the received comments from 
reviewers. 
 All authors contributed to the work described in the paper, and take responsibility 
for it. Further, none of the described work has been published elsewhere. 
 We would be grateful if you would consider this revised manuscript for 
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The use of poly-(D,L-lactic-co-glycolic) acid (PLGA) particles as carriers for DNA 25 
delivery has received considerable attention in mammalian studies. DNA vaccination of 26 
fish has been shown to elicit durable transgene expression, but no reports exist on 27 
intramuscular administration of PLGA-encapsulated plasmid DNA (pDNA). We injected 28 
Atlantic salmon (Salmo salar L.) intramuscularly with a plasmid vector containing a 29 
luciferase (Photinus pyralis) reporter gene as a) naked pDNA, b) encapsulated into 30 
PLGA nano- (~320nm) (NP) or microparticles (~4µm) (MP), c) in an oil-based 31 
formulation, or with empty particles of both sizes. The ability of the different pDNA-32 
treatments to induce transgene expression was analyzed through a 70-day experimental 33 
period. Anatomical distribution patterns and depot effects were determined by tracking 34 
isotope labeled pDNA. Muscle, head kidney and spleen from all treatment groups were 35 
analyzed for proinflammatory cytokines (TNFα, IL-1β), antiviral genes (IFN-α, Mx) and 36 
cytotoxic T-cell markers (CD8, Eomes) at mRNA transcription levels at days 1, 2, 4 and 37 
7. Histopathological examinations were performed on injection-site samples from days 2, 38 
7 and 30. Injection of either naked pDNA or the oil-formulation was superior to particle 39 
treatments for inducing transgene expression at early time-points. Empty particles of both 40 
sizes were able to induce proinflammatory immune responses as well as degenerative and 41 
inflammatory pathology at the injection site. Microparticles demonstrated injection-site 42 
depots and an inflammatory pathology comparable to the oil-based formulation. In 43 
comparison, the distribution of NP-encapsulated pDNA resembled that of naked pDNA, 44 
although encapsulation into NPs significantly elevated the expression of antiviral genes 45 
in all tissues. Together the results indicate that while naked pDNA is most efficient for 46 
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inducing transgene expression, the encapsulation of pDNA into NPs up-regulates 47 

























PLGA (poly-(D,L-lactic-co-glycolic)-acid) nano- and microparticles as adjuvants and 71 
carriers for vaccine antigens have been extensively investigated, mainly in mammalian 72 
models [1-5]. The biodegradable copolymer produces non-toxic degradation products [3], 73 
offers increased predictability of antigen release-rates, potential for intracellular antigen 74 
delivery and the ability to encapsulate and co-encapsulate a wide variety of antigens, 75 
including DNA vaccines [1, 6, 7]. 76 
Luciferase has commonly been applied for the evaluation of DNA vaccines at 77 
both transcription and protein level, and appears to express higher in fish than in 78 
mammals for a given dose of DNA [8-12]. The encapsulation of plasmid DNA into 79 
PLGA particles could protect against the rapid on-site degradation reported in both mice 80 
and salmon after intramuscular injection, and has been shown to increase the escape of 81 
antigen from endosomes to the cytosol [6, 8, 10, 11, 13].  82 
Depending on size, the particles may create injection-site depots (>5µm), get 83 
phagocytized by antigen presenting cells (APCs) (<5µm), be internalized by non-84 
phagocytic cells such as myocytes (<500nm) or escape into the bloodstream and 85 
subsequently be cleared by phagocytes in the head kidney, spleen and/or liver [4, 14]. 86 
Muscle cells have been shown to slowly accumulate pDNA over time, and could benefit 87 
from extracellular pDNA-releasing microparticles as well as intracellular nanoparticle 88 
depots [15]. 89 
A central attribute of DNA vaccines is the ability to induce cellular as well as 90 
humoral immune responses, including cytotoxic T-lymphocyte (CTL) responses and 91 
antibody production [16-18]. Unlike vertebrate DNA, bacterial DNA contains stretches of 92 
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unmethylated CpG sequences that are recognized as danger signals by toll-like receptor 9 93 
(TLR9). Upon stimulation this endosomal pattern recognition receptor (PRR) may induce 94 
a variety of cytokines. Interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) are 95 
hallmark cytokines in driving the inflammatory response in mammals and amongst other 96 
properties hold key roles in the migration of effector cells to sites of infection [19]. Both 97 
cytokines have been found in a number of teleost species and appear to exert functions 98 
similar to what is known from mammals [20-22].  99 
Interferon-α (IFN-α) is one of the type I IFNs, key mediators of antiviral 100 
responses through the regulation of IFN-stimulated genes and central in linking innate 101 
and adaptive immunity [16, 23-25]. The IFN-induced protein Mx has demonstrated 102 
antiviral functions in Atlantic salmon (Salmo salar L.) and can be used to follow IFN 103 
activity, as it has a much longer lifetime and accumulates to higher concentrations [26-104 
28]. Type I IFNs also play an important role in the clonal expansion and generation of 105 
specific as well as non-specific memory CD8
+
 T-cells [29]. Sequences for CD8α and 106 
CD8β are known from a variety of teleost species and the cytotoxic activity of CD8
+
 T-107 
cells has been demonstrated in rainbow trout (Oncorhynchus mykiss) [30, 31]. The 108 
transcription factor Eomesodermin (Eomes) is critical to the development of CD8
+
 T-cell 109 
effector functions and memory cells in mammals [32, 33]. A recent study indicated 110 
similar functions  as well as induction by IFN-α in Atlantic salmon [34].  111 
Intramuscular injection of naked pDNA generally induces few and transient 112 
histopathological changes in fish as well as in mammals [9]. In contrast, the use of PLG 113 
microspheres as DNA carriers has been shown to result in a foreign body response in 114 
mice, where the infiltrating cells were also the ones that were primarily transfected [35]. 115 
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Enhanced inflammatory reactions coupled with prolonged availability of pDNA might 116 
therefore be beneficial to transgene expression and T-cell responses. 117 
This report is the first on intramuscular injection of Atlantic salmon with PLGA 118 
nano- and microparticles carrying pDNA, and the effect of these particles on 1) tissue 119 
distribution and retention of pDNA 2) expression of a firefly (Photinus pyralis) luciferase 120 
reporter gene 3) innate inflammatory (TNF-α, IL-1β) and antiviral (IFN-α, Mx) immune 121 
responses, 4) expression of cytotoxic T-cell markers (CD8, Eomes) and 5) injection site 122 
histopathology. We hypothesize that PLGA-encapsulated pDNA will induce transgene 123 
expression and proinflammatory as well as antiviral responses more efficiently than non-124 
encapsulated pDNA. 125 
 126 
 127 
2. Experimental 128 
2.1 Materials/Chemicals 129 
Poly(D,L-lactic-co-glycolic) acid (PLGA; 50:50 ratio, Mw of 7-17 kDa), poly vinyl 130 
alcohol (PVA, 87-89 % hydrolyzed), D-(+)-trehalose dehydrate, 1,3,4,6-tetrachloro-3α, 131 
6α-diphenylglycouril (Iodogen; Pierce, Rockford, IL, USA), Freund’s incomplete 132 
adjuvant (FIA)  and quantitative polymerase chain-reaction (QPCR) primers were 133 
purchased from Sigma Aldrich. Carrier free Na[
125
I] was from Perkin-Elmer Norge 134 
(Oslo, Norway). Acetone, dichloromethane (DCM) and chloroform were purchased from 135 
Merck Biochemicals. Sodium metabisulphite (Na2S2O5 > 98 % purity) and potassium 136 
iodide (KI > 99.5 % purity) were purchased from Fluka Biochemica. Luciferase 137 
lyophilizate was purchased from Roche Diagnostics GmbH (Mannheim, Germany).  138 
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2.2 Plasmid DNA 139 
Plasmid R70pRomiLuc (gift from Uwe Fischer, Friedrich-Loeffler-Institut, Germany) 140 
contains a firefly luciferase gene under the control of a murine cytomegalovirus 141 
immediate early promoter (CMV-IEP). The plasmid was isolated from a culture of 142 
Escherichia coli (strain DH5α) by use of Qiagen Plasmid Giga Kit (Qiagen GmbH, 143 
Hilden, Germany) according to manufacturer instructions. Purified plasmid was eluted in 144 
Tris-EDTA (TE) buffer (pH=8.0). DNA concentration and quality was determined with a 145 
NanoDrop® ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, 146 
USA) and 1% agarose gel-electrophoresis. High quality samples (A260/A280 ratio > 1.9 147 
and distinct DNA bands on gel) were stored at -20 ºC until use. 148 
 149 
2.3 Preparation of [
125
I]-fluorescein-pDNA 150 
Purified pDNA was modified using the nucleic acid labeling kit LabelIT Fluorescein 151 
(MIR 3200, Mirus Corp., Madison, WI, USA) according to manufacturer instructions. 152 
Radiolabeling of f-pDNA with carrier-free Na[
125
I] was performed in a direct reaction 153 
with 1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril as the oxidizing agent. The protocol 154 
was in accordance with the Iodogen method of radiolabeling [36], with minor 155 
modifications concerning incubation time (1h). Free iodine was removed by filtration on 156 
a PD-10 column equilibrated with pDNA in PBS. Radiation was determined by gamma 157 
counting (COBRA™ II Auto-Gamma®, ©Packard Instrument Co., Meridan, IL, USA), 158 









2.4 Preparation of naked and pDNA-loaded nano- and microparticles 162 
Particles were prepared by a modified version of the double emulsion (W1/O/W2) solvent 163 
evaporation method [2, 5, 37], outlined in table 1. A fraction of 
125
I-f-pDNA was 164 
included in the first water phase (W1) for determination of encapsulation efficiency and 165 
tracing of tissue distribution in in vivo experiments. Emulsions were prepared on ice-166 
baths by sonication (S) (Sonics VibraCell VC750, 3 mm tapered micro tip, Sonics & 167 
Materials Inc., Newtown, CT, USA) or homogenization (H) (Ultra-turrax® T-25 Basic, 168 
IKA®-WERKE, Staufen, Germany). Plasmid was excluded from the W1 phase for 169 
preparation of naked particles. Fifteen ml dH2O was added to the W1/O/W2-emulsions 170 
before overnight stirring to facilitate solvent evaporation. After centrifugation (Avanti® 171 
J-26 XP, BeckmanCoulter®, USA), pellets were resuspended in dH2O and the fractions 172 
were pooled. Trehalose (5 mg ml
-1
 in dH2O) was used as a lyoprotectant and added to 173 
suspension aliquots in a ratio of 1:3. Aliquots were kept at -80˚C for a minimum of 2 h 174 
before lyophilization for 72 h at 0.001 hPa, -110 °C (ScanVac CoolSafe
TM
, LaboGene, 175 
Denmark). Lyophilizates were stored in airtight containers at 4 °C. 176 
 177 
2.5 Particle characterization 178 
Encapsulation of pDNA was determined by the gamma emission in a known amount of 179 
particles (COBRA™ II Auto-Gamma®) and measured radioactivity related to the 180 
specific radioactivity in the fraction of 
125
I-f-pDNA stock solution added to the W1-phase. 181 
Encapsulation efficiency was determined as entrapped amount of pDNA relative to the 182 
amount initially present in the W1-phase. Loading (µg pDNA mg
-1
 PLGA) was calculated 183 
by relating encapsulated pDNA to the total weight of retrieved particles. Sizing of 184 
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nanoparticles was performed by photon correlation spectroscopy (PCS) (NiComp 380 185 
Submicron Particle Sizer, Santa Barbara, USA). Microparticle size was determined by 186 
use of a Model 780 AccuSizer (NiComp). 187 
 188 
2.6 In vitro particle stability and pDNA release 189 
Five containers of 10 mg lyophilizate dissolved in 1 ml PBS (pH 7.4) with 0.02% sodium 190 
azide (NaN3) were prepared for both nano- and microparticles. The suspensions were 191 
incubated at 8˚C on a Stuart® SB3 rotator. Sampling was performed immediately after 192 
particles had been dissolved, and then at 3 h, day 1, 2, 4, 7, 14, 21, 30, 40, 50, 60 and 70. 193 
At each sampling 100 µl were removed and centrifuged at 15,000 x g for 1 minute. Fifty 194 
µl of the supernatant were removed for isotope measurement, and the remaining fraction 195 
transferred back to the original container after addition of 50 µl new PBS and full re-196 
suspension of the particle pellets. 197 
 198 
2.7 Fish 199 
Unvaccinated pre-smolt Atlantic salmon with a mean weight of 30 g were provided by 200 
and kept at Tromsø Aquaculture Research Station. The fish were kept in 200 L plastic 201 
tanks supplied with running fresh water (8-10˚C) and fed a commercial feed from 202 
Skretting AS (Stavanger, Norway). Adaptation to test conditions was performed for one 203 
week prior to immunization. All experiments were in compliance with The Norwegian 204 





2.8 Experimental groups and vaccination 208 
A total of 336 fish were distributed among seven tanks. Each tank contained 6 fish from 209 
each of the eight experimental groups (Table 2). Prior to tattooing and immunization the 210 
fish were sedated with benzocaine using 40 mg L
-1
 (Benzoak Vet., ACD 211 
Pharmaceuticals, Leknes, Norway). The PanJet needle free injection system with 212 
saturated Alcian blue was used for tattooing. All formulations were administered in 50 µl 213 
volumes by injection in the left epaxial muscle. Each injection dose contained 11 µg 214 
pDNA, and the amount of NPs and MPs was adjusted to make up for differences in 215 
pDNA loading. Injection dose samples were collected from each formulation in order to 216 
determine cpm. 217 
 218 
2.9 Sampling 219 
The fish were starved for 24 h prior to sampling and killed by a double dose (80 mg L
-1
) 220 
of benzocaine. At day 1, 2, 4, 7, 14, 30 and 70 post injection one tank was sampled. All 221 
fish were weighed. Blood from fish given radioactive formulations was sampled using 222 
vacutainers (Becton Dickinson) and stored on ice. Two muscle samples from the 223 
injection site were transferred to 10% neutral buffered formalin for storage until 224 
histological processing. Muscle samples, spleens and head kidneys were transferred to 225 
separate tubes containing 1 ml RNAlater® (Ambion, Austin, TX, USA) and kept at room 226 
temperature overnight before storage at -20˚C. To determine tissue distribution in fish 227 
given radioactive formulations it was necessary to sample the full carcass. Trunk kidney, 228 
organ package (liver, heart, gastrointestinal tract (GIT) and interstitial adipose tissue), 229 
head (incl. gills) and remaining muscle (with skin) were collected in separate tubes. One 230 
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fish injected only with PBS was similarly sampled at each time point in order to exclude 231 
the possibility of radioactive contamination by cohabitation. 232 
 233 
2.10 Anatomic distribution and plasmid DNA retention 234 
Determination of in vivo retention and biodistribution was achieved by tracking trace 235 
amounts of 
125
I-f-pDNA. From blood samples, 50 µl were removed for analysis. 236 
Radioactivity in blood and trunk kidney samples was determined with a COBRA™ II 237 
gamma counter. Remaining samples, including spleen and injection site tissue, were 238 
analyzed using a Packard Auto-Gamma Scintillation Spectrometer (©Packard Instrument 239 
Co., model 5120). Background radiation was measured to be 50 and 100 cpm 240 
respectively for the two machines. These were set as baselines, and were subtracted from 241 
measured values before data were adjusted according to [
125
I] half-life. Blood volume 242 
was set to 4% of the body weight [38]. Mean values of the injection dose samples 243 
gathered during vaccination were used to determine total cpm recovery (%) at day 1. To 244 
determine the stability of retention, the daily cpm means were related to recovery at day 245 
1. Daily cpm means were used to determine anatomical distribution. 246 
 247 
 2.11 RNA isolation and cDNA synthesis 248 
Tissue samples (20-30 mg) were removed from RNAlater® and homogenized in lysis 249 
buffer from the RNeasy mini kit (Qiagen) using tubes with ceramic beads (Precellys) and 250 
a Precellys® 24 Homogenizer (Bertin Technologies). Parameters were set for 5300 x g x 251 
3 spins, 10 s. Subsequent RNA extractions and on-column purification with the RNase-252 
Free DNase Set from Qiagen were performed according to manufacturer instructions. 253 
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RNA was eluted in 50 µl RNase-free water and stored at -80˚C until use. RNA 254 
concentration and quality was determined using NanoDrop® (NanoDrop Technologies) 255 
and 1% agarose gel electrophoresis. High quality samples (260/280 ratio > 1.9 and tight 256 
18S/28S bands) were used for cDNA synthesis. Reverse transcription was performed 257 
with the High Capacity RNA-to-cDNA Master-mix from Applied Biosystems in 258 
accordance with manufacturer instructions. Each reaction contained 400 ng RNA in 20 259 
µl. Samples were diluted to 80 µl with RNase-free water and stored at -80˚C.  260 
 261 
2.12 Quantitative reverse transcription polymerase chain reaction (QPCR) 262 
Quantitative PCR was performed according to manufacturer instructions using Fast 263 
SYBR® Green Master Mix (Applied Biosystems) and primers previously applied in our 264 
laboratory (Table 3). Primer efficiency was determined using a six-point 1:2 dilution 265 
series in triplicate, with an initial cDNA concentration of 20 ng. All primers were free of 266 
primer-dimers in no-template control and showed a single peak in the dissociation curve. 267 
Samples containing 20 ng cDNA were run in triplicate, with each plate including no-268 
template control and an inter-run calibrator. Analysis was performed on a 7500 Fast Real-269 
Time PCR System (Applied Biosystems) with the thermal cycler profile set to 95˚C for 270 
20 s, 40 cycles of 95˚C for 3 s and 40 cycles of 60˚C for 30 s. Dissociation curves were 271 
performed on all samples. The 7500 Software Relative Quantification Study Application 272 
(v2.0.4, Applied Biosystems) was used to determine CT values, with walking baseline 273 
and threshold set manually to be equal for all genes. Relative gene expression was 274 
determined by the Pfaffl method [39], comparing saline injected fish to treated groups. 275 
To determine relative expression of luciferase the highest day 1 transcript average was 276 
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used as control. Head kidney and spleen samples from day 2 and 7 were also checked for 277 
luciferase transcripts. 278 
 279 
2.13 Histology 280 
Muscle samples from days 2, 7 and 30 post injection were chosen for histology. The 281 
service of routine histological processing and staining with hematoxylin and eosin (HE) 282 
was purchased from the National Veterinary Institute (Oslo, Norway). Sections were 283 
studied by light microscopy for signs of hemorrhages, tissue degradation and 284 
inflammation. Using the changes in day 2 saline injected fish as a baseline, observed 285 
changes were classified as either moderate (+) or strong (++). Moderate changes were 286 
determined as largely limited to the needle trajectory, with inflammatory cells primarily 287 
associated with degenerated tissue and/or dispersed among intact muscle cells. Strong 288 
changes were seen as degeneration and/or inflammation spreading beyond the needle 289 
trajectory, with few or no intact muscle cells present within the cellular infiltrate. The 290 
histopathology scores were performed as blind testing by two people. 291 
  292 
2.14 Statistical analysis 293 
Microsoft Excel (Microsoft™) was used for arrangement of data as well as calculation of 294 
biodistribution and relative gene expression. Statistical analyses for real-time PCR were 295 
performed with IBM SPSS (Statistical Package for the Social Sciences, version 19.0). All 296 
data were natural log transformed prior to analysis, and normality verified by the 297 
Shapiro-Wilk test. Levene’s test of equality of variances was used to check for 298 
homoscedasticity. Homoscedastic data were analyzed by one-way ANOVA with Tukey 299 
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as the post hoc test. Where homoscedasticity was violated, the Welch test of equality of 300 
means was applied, followed by Dunnett T3 post hoc. Graphs were constructed with 301 
Microsoft Excel and SPSS. 302 
 303 
 304 
3. Results 305 
3.1 Particle characterization 306 
The encapsulation efficiency and loading of 
125
I-f-pDNA were low for both particles 307 
sizes. The different particle characteristics are summarized in table 1, where empty 308 
particles have been excluded due to minor size differences. The mean size of 309 
nanoparticles was 320 nm by intensity distribution, with more than 90% measuring less 310 
than 500 nm. The number weight mean diameter of microparticles was 3-4 µm, with 80% 311 
measuring less than 5 µm and more than 90% smaller than 10 µm.  312 
 313 
3.2 In vitro particle stability and pDNA release 314 
Neutral pH and a temperature of 8˚C were chosen in order to simulate in vivo conditions. 315 
Initial burst release was 81% for NP-(
125
I-f-pDNA) and 49% for MP-(
125
I-f-pDNA). Both 316 
groups subsequently displayed a slow and sustained release, with a 96% and 69 % 317 
accumulated release at day 70 (Fig. 1). 318 
 319 
3.3 Anatomical distribution and depot of vaccine formulations 320 
No radioactivity was registered in blood later than day 7 post injection. The average total 321 
cpm recovery at day 1 ranged from 15% for NP-(
125





(results not shown). Radioactivity was primarily recovered from the injection site, organs 323 





I-f-pDNA (Fig. 2A, B). Likewise, MP-(
125
I-f-pDNA) and FIA-325 
(
125
I-f-pDNA) had similar distribution profiles and injection site depots (Fig. 2C, D). The 326 





containing almost 80% of total radiation at day 70. NP-(
125
I-f-pDNA) showed higher 328 
injection site retention (5%) at day 70 compared to 
125





I-f-pDNA) were 34% and 26%, with retention 330 
in trunk kidney reaching 32% and 27% at day 70.  331 
 332 
3.4 Quantitative reverse transcription polymerase chain reaction (QPCR) 333 
3.4.1 Expression of luciferase reporter gene 334 
FIA-(
125
I-f-pDNA) induced the highest luciferase transcript average in muscle at day 1 335 
and was chosen as calibrator for this tissue. FIA-(
125
I-f-pDNA) also induced the highest 336 
individual levels of luciferase transcripts throughout the experiment, with significant 337 
expression at day 1, 4 and 14 (p ≤ 0.032) (Fig. 3). Naked plasmids consistently induced 338 
higher expression than the particle formulations, with significance for pDNA at day 1-7 339 
(p ≤ 0.042) and 
125
I-f-pDNA at day 4 (p = 0.018). No significant differences were found 340 
at days 30 and 70. Low luciferase transcript levels were detected in head kidney, with 341 
pDNA and 
125
I-f-pDNA inducing significant expression compared to NP-
125
I-f-pDNA at 342 





3.4.2 Proinflammatory cytokines IL-1β and TNF-α 346 
The particle formulations significantly up-regulated IL-1β in muscle samples at all time-347 
points; NP-(
125
I-f-pDNA) (p ≤ 0.002), NP (p ≤ 0.004), MP-(
125
I-f-pDNA) (p ≤ 0.003), 348 
MP (p ≤ 0.015) (Fig. 4A). From day 2 the up-regulation was significant compared to all 349 
non-particle groups. MP formulations consistently induced the highest expression. FIA-350 
(
125
I-f-pDNA) significantly up-regulated IL-1β in muscle at day 7 (p = 0.000). Significant 351 
expression of TNF-α in head kidney was only found at day 4, with NP-(
125
I-f-pDNA) (p 352 
= 0.034) and MP (p = 0.008) (Fig. 4B). No significant expression of TNF-α was found in 353 
the spleen or muscle. 354 
 355 
3.4.3 IFN-α and Mx 356 
NP-(
125
I-f-pDNA) significantly up-regulated IFN-α at the injection site at day 4 (p = 357 
0.005). Levels in head kidney were generally low, with significant up-regulation by 
125
I-358 
f-pDNA (p = 0.000) at day 2. NP-(
125
I-f-pDNA) (p ≤ 0.003) and NP (p ≤ 0.036) 359 
significantly up-regulated IFN-α in spleen at day 1 and 2 (results not shown). Levels of 360 
Mx at the injection site increased for all groups from day 1 to 7. NP-(
125
I-f-pDNA) 361 
induced significant expression at day 2-7 (p = 0.000), and was superior to all groups at 362 
day 4 and 7 (p ≤ 0.020). MP-(
125
I-f-pDNA) significantly up-regulated Mx in muscle at 363 
day 2 and 4 (p ≤ 0.006) (Fig. 5A). NP-(
125
I-f-pDNA) appeared the most potent treatment 364 
for inducing Mx in head kidney, but no significance was found (Fig. 5B). Mx expression 365 
increased in spleen for all groups from day 1 to 7, with significance for NP-(
125
I-f-pDNA) 366 




3.4.4 CD8 and Eomes 369 
There was no significant up-regulation of CD8 in any tissue. Several muscle samples 370 
showed no CD8 expression, and no statistical analyses could therefore be performed. 371 
No expression of CD8 could be detected at day 2 in head kidney samples from fish 372 
injected with 
125
I-f-pDNA. Interestingly, these samples induced the only significant up-373 
regulation of Eomes observed within any tissue (p = 0.000) (results not shown). 374 
 375 
3.6 Histopathology 376 
Tissue sections of injection site samples were examined by light microscopy for signs of 377 
hemorrhages, muscle degeneration and inflammation (Table 4). PBS caused only minor 378 
hemorrhages and tissue degeneration at day 2 (Fig. 6A), indicating that later changes 379 
were likely the results of the different treatments. Hemorrhages were most pronounced at 380 
day 2 in all groups. Administration of PBS and 
125
I-f-pDNA caused moderate muscle 381 
degeneration, but no inflammation. Both tissue degeneration and inflammation were 382 





I-f-pDNA) both demonstrated strong 384 
inflammation at day 30 (Fig. 6B, D), with a high influx of inflammatory cells that for 385 
FIA-(
125
I-f-pDNA) was concentrated around possible oil-droplets. The histopathological 386 
changes caused by particles seemed to depend on particle size (nano vs. micro) rather 387 






4. Discussion 392 
The use of PLGA particle constructs as carriers for DNA vaccine delivery has so far 393 
received little attention in fish studies [1, 40]. We have investigated distribution/depot, 394 
transgene and immune gene transcription as well as injection site histopathology 395 
following intramuscular injection of Atlantic salmon with PLGA particles carrying 396 
pDNA encoding luciferase. The double emulsion solvent evaporation method [2, 37] was 397 
used to prepare nano- and microparticles with mean diameters of 320 nm and 4 µm, 398 
respectively. Low pDNA encapsulation appears to be a recurring problem, and our results 399 
(<30% for both particle sizes) are supported by other studies [12, 35]. 400 
One of the challenges of conventional DNA vaccination is the rapid tissue 401 
clearance and on-site degradation of DNA, which may result in reduced pDNA uptake 402 
and transgene expression [8, 10]. Although oil adjuvants are not commonly applied for 403 
intramuscular vaccine delivery, FIA-(
125
I-f-pDNA) provided a positive control to 404 
measure the depot potential of nano- and microparticles. The high burst release observed 405 
for NP-(
125
I-f-pDNA) during the in vitro release study (Fig. 1) likely explains the strong 406 
similarities between this group and 
125
I-f-pDNA (Fig. 2A, B), a similarity reflected also 407 
in the injection site histopathology (Table 4). In comparison, the injection site retention 408 
of MP-(
125
I-f-pDNA) remained similar to that of FIA-(
125
I-f-pDNA) throughout the study 409 




I-f-pDNA) depots likely 410 
contributed to the severe histopathological inflammations observed in tissue sections 411 
from both groups at day 30 (Fig. 6B, D). The transfection of infiltrating cells has been 412 
shown to take place in both fish and mammals [35, 37, 41], and transient inflammatory 413 
responses may thus contribute to increased transgene expression. Long lasting 414 
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I-f-pDNA) are, however, 415 
undesirable in a product meant for consumption. It would appear that nanoparticles may 416 
be favorable in order to avoid potential tissue damage, but the small sample sizes meant 417 
we could only obtain an indication of the histopathological influence of the various 418 
treatments. 419 
Although the similarities in injection site retention were not reflected in the 420 
expression of the luciferase transgene (Fig. 3), the observation that FIA-(
125
I-f-pDNA) 421 
induced the highest individual levels of luciferase transcripts suggests that increased 422 
cellular infiltration along with a high injection site pDNA depot may be of benefit to 423 
transgene expression in Atlantic salmon. The significantly lower expression obtained 424 
with encapsulated pDNA could be a result of the preparation conditions, as the W1/O/W2 425 
method has been shown to cause a partial reduction in the content of supercoiled (SC) 426 
DNA topoform that contributes to a lower transfection efficiency [1, 8, 37, 42]. The 427 
process of emulsification required lower shear forces and shorter duration of preparation 428 
and may thus have preserved a larger portion of SC DNA in FIA-(
125
I-f-pDNA). We did 429 
not, however, address whether the encapsulation of 
125
I-f-pDNA resulted in an altered SC 430 
content. The absence of significant differences in luciferase expression at day 30 and 70 431 
still indicated a certain level of stability in particle groups that could result from a 432 
continued release of bioactive pDNA even at later time-points. 433 
Another explanation for the low transcription levels obtained with encapsulated 434 
pDNA-Luc may lie with the inflammatory cytokine responses. Induced not only by 435 
stimulation of PRRs but also by PLGA itself [43, 44], IL-1β and TNF-α have both 436 
demonstrated inhibitory effects on transgene expression even at low concentrations, 437 
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contributing to a reduced transfection efficiency of encapsulated DNA in vivo as opposed 438 
to in vitro [2, 37, 45]. The nano- and microparticle formulations significantly up-439 
regulated IL-1β at the injection site at all time-points (Fig. 4A), and while the expression 440 
of TNF-α was generally low a synergistic effect of different cytokines on the inhibition of 441 
transgene expression has been reported [45]. In comparison, the levels of IL-1β in fish 442 
injected with FIA-(
125
I-f-pDNA) were not found significant until 7 days post 443 
administration, indicating that PLGA may provide a more potent inflammatory stimulus 444 
than the oil adjuvant even in the absence of pronounced inflammatory histopathology. 445 
Viral challenge studies in fish have shown that specific protection may be 446 
acquired even with very low doses of DNA, and innate antiviral responses also appear to 447 
play a more critical role in fish than mammals upon exposure to viruses [46, 47]. 448 
Whereas luciferase is unlikely to induce a differentiation of antigen specific CD8
+
 T-cells 449 
due to low immunogenicity in in vivo studies [48, 49], type I IFNs play an important role 450 
in the clonal expansion of CD8
+
 T-cells and may enhance CTL responses when 451 
immunogenic transgene products are expressed [29]. Whereas the expression of IFN-α 452 
was generally low and transient, NP-(
125
I-f-pDNA) still appeared the most potent inducer 453 
of antiviral responses and significantly up-regulated the expression of Mx in all tissues 454 
(Fig. 5). This result supports a previous study on the influence of particle size on the 455 
cytokine profile induced after administration of particle associated CpG DNA [50]. We 456 
did observe that formulations with naked pDNA significantly up-regulated both Eomes 457 
and IFN-α in head kidney at day 2, but no statistical correlation between these genes was 458 
found for any other group, tissue or time-point. 459 
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This study is the first on intramuscular injection of Atlantic salmon with PLGA 460 
particles carrying pDNA. Our particle formulations did not induce transgene expression 461 
as efficiently as injection of naked plasmids, but appeared to provide a continued release 462 
of bioactive pDNA even at the end of the study. A strong expression of transgene may 463 
not always be necessary in order to mount a significantly protective immune response, 464 
and an efficient up-regulation of innate antiviral responses in particular might enhance 465 
the immunogenicity of an antiviral vaccine. Both particle sizes proved superior to naked 466 
pDNA injection for the induction of IL-1β as well as an influx of inflammatory cells at 467 
the injection site, but only encapsulation into nanoparticles significantly increased the 468 
expression of IFN-α and Mx. Together these results indicate that PLGA nanoparticles as 469 
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Response to review of manuscript with title “Transgene and immune gene 
expression following intramuscular injection of Atlantic salmon (Salmo salar L.) 
with DNA-releasing PLGA nano- and microparticles”. 
 
 
General comments on the revised manuscript: 
For this re-submission revisions have been confined to the introduction and 
discussion sections of the manuscript, in addition to some figure revisions in response to 
reviewer’s queries. As the study was not designed to evaluate DNA vaccine efficacy but 
rather the potential influence of various factors on the expression of a reporter gene, we 
found it right not to make too much speculation as to how our results might transfer to an 
actual DNA vaccine trial. An effort has instead been made to clarify the various results 
and observations in terms of their potential impact – positive or negative – on the 
expression of the reporter gene. 
New additions as well as altered sections of the text have been highlighted in red 
for easier recognition, and line-references have also been provided in the answers to 















In the abstract there are several “pDNA”. The authors should clarify what “p” stands 
for in the first one. 
Clarification has been made in line (L) 28. 
 
Query 2: 
The authors have used a luciferase gene as a reporter gene in the present study. If the 
authors have been tried a luciferase assay in this project, the authors should show the 
results of the assay. If not, the author should describe the reason why a luciferase gene 
has been chosen as a reporter gene. 
No luciferase assay was included in the current project. Luciferase (Luc) was still 
chosen as it is one of the most common reporter genes and has frequently been applied 
for the evaluation of transgene expression in fish at both protein and transcription level 
(L77-79). The application of a Luc-gene hence makes it easier to evaluate and relate the 
work performed for this manuscript to previously published studies. 
 
Query 3: 
In the results of histopathology, it is difficult to understand the histological differences 
between treated samples and controls for those who are not familiar with the inflamed 
tissue. 
a) Please describe the detailed features of muscle degeneration and inflammation in the 
manuscript or figure legend. 
More detailed descriptions of the various histopathological features including 
muscle cell degeneration and inflammation have been provided in the figure legend. 
b) Please add the enlarged figures for the inflammatory cells and add the description of 
the detailed features for the inflammatory cells in fig 6D. 
Detailed features, such as cell types, cannot be provided for the observed 
inflammatory cells as no immunohistochemical assays were conducted to verify their 
specific nature. A higher magnification micrograph has been provided for one of the 
original, lower magnification sections to show the high variation in infiltrating cells. 
 
c) Please add scale bars for the panels in histological figures. 
Scale bars have been added. 
 
Query 4: 
Although several homolog genes were used as markers for pro-inflammatory, antiviral 
response and cytotoxic T-cell markers in the present study, the authors should show some 
proofs that those genes had similar roles in Atlantic salmon by the referring of previous 
other work, or other way. 
The introduction has been altered to include specific references to studies on 
function and/or presence of the various cytokines and markers in fish species. For TNF-α 
and IL-1β the additions can be found in L95-99. Studies on the activities of IFN-α and 
Mx in teleosts were referenced in the previous draft. Descriptions are now given in L100-
106. Brief references to the existence and activity of CD8 in fish have also been made 
(L106-108), while reference to a very recent study on the expression and function of 
Eomesodermin in Atlantic salmon has been included in L108-111- 
 
Query 5: 
The authors should add the evidence-based descriptions that the early response (1-7 days 
post vaccination) of immune-related genes showed in the fig. 4 and 5 would be of benefit 
to DNA vaccination in the discussion part. 
Whereas some mention had been made to the benefit of these early responses, we 
agree that the original manuscript did not clarify the findings and evaluations of these in a 
satisfactory manner. The discussion has therefore to some extent been rewritten to clarify 
potential benefits as well as negative effects of the various early immune responses. 
The role of proinflammatory cytokines in the migration of inflammatory cells to the site 
of injection has been specified in the description of biological function (L95-97), whereas 
the potential influence of these cytokines on DNA vaccines and transgene expression is 
described in L434-442. Likewise, the antiviral functions of IFN-α and Mx and the 
relation to CD8 and Eomes expression can be found in the introduction, as described for 
query 4. In the discussion, L448-449 and L451-453 reference the importance of innate 
antiviral responses in teleosts and presents the potential benefit to later, acquired 
responses. In L455-457 a reference is given to the potential influence of PLGA particle 
size on the resulting antiviral response. 
             
Figure 1 - Release of 125I-f-pDNA from nano- and microparticles through 70 days of incubation at 8˚ C, presented as the mean 
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Figure 2 – Radioactivity recovered from samples of trunk kidney (TK), organs (Org) and injection site (I.S.). The stacked bars 
represent the relative distribution of pDNA among these organs in groups A) NP-(125I-f-pDNA), B) 125I-f-pDNA, C) MP-(125I-f-
























Figure 3 - Relative expression of luciferase mRNA transcripts in muscle from the injection site through the 70 day sample 
period. The box-plot shows the median value (line) and maximum and minimum values (whiskers), with the box representing 
50% of the samples. Circles show outliers. The highest cpm-average at day 1 was found in group FIA-(125I-f-pDNA) and was 














































Figure 4 – Relative expression of proinflammatory cytokines; A) IL-1β in muscle from the injection site and B) TNF-α in head 
kidney. The box-plot shows the median value (line) and maximum and minimum values (whiskers), with the box representing 

























































Figure 5 - Expression of the antiviral protein Mx in A) injection site muscle, B) head kidney and C) spleen. The box-plots show 
median values (line) and maximum and minimum values (whiskers), with the boxes representing 50% of the samples. Circles 


























Figure 6 – All pictures show transversal sections of skeletal muscle from the injection site, stained with hematoxylin and eosin 
(HE). A) Minor hemorrhages (arrow) and muscle cell degeneration in negative control (PBS) group observed at day 2.  B) 
Massive cellular infiltrate in the myocyte fibre and surrounding interstitium at day 30 in tissue of fish injected with MP-(125I-f-
pDNA). Magnification of cellular infiltrate is shown with a 10.0 µm scale-bar. C) Focal muscle cell degeneration (star) and 
minor hemorrhages (arrows) can be seen at day 7 in samples from fish injected with pDNA.  D) Large oil-droplets 
(arrowheads) surrounded by degenerative muscle fibers and inflammatory cells at day 30 after injection of FIA-(125I-f-pDNA). 
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We are pleased to have the referees’ comments, and we have now undertaken the 
revision that hopefully fulfills the requirements to get the manuscript accepted. 
 
In general, we have met the criticisms made by the referees, and performed the 
revision accordingly. In addition we have made some minor additional 
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The authors have used a luciferase gene as a reporter gene in the present study. If the 
authors have been tried a luciferase assay in this project, the authors should show the 
results of the assay. If not, the author should describe the reason why a luciferase gene 
has been chosen as a reporter gene. 
No luciferase assay was included in the current project. Luciferase (Luc) was still 
chosen as it is one of the most common reporter genes and has frequently been applied 
for the evaluation of transgene expression in fish at both protein and transcription level 
(L77-79). The application of a Luc-gene hence makes it easier to evaluate and relate the 
work performed for this manuscript to previously published studies. 
 
Query 3: 
In the results of histopathology, it is difficult to understand the histological differences 
between treated samples and controls for those who are not familiar with the inflamed 
tissue. 
a) Please describe the detailed features of muscle degeneration and inflammation in the 
manuscript or figure legend. 
More detailed descriptions of the various histopathological features including 
muscle cell degeneration and inflammation have been provided in the figure legend. 
b) Please add the enlarged figures for the inflammatory cells and add the description of 
the detailed features for the inflammatory cells in fig 6D. 
Detailed features, such as cell types, cannot be provided for the observed 
inflammatory cells as no immunohistochemical assays were conducted to verify their 
specific nature. A higher magnification micrograph has been inserted for one of the 
originals (6B) to show the high variation in infiltrating cells. 
 
c) Please add scale bars for the panels in histological figures. 
Scale bars have been added. 
 
Query 4: 
Although several homolog genes were used as markers for pro-inflammatory, antiviral 
response and cytotoxic T-cell markers in the present study, the authors should show some 
proofs that those genes had similar roles in Atlantic salmon by the referring of previous 
other work, or other way. 
The introduction has been revised accordingly to include specific references to 
studies on function and/or presence of the various cytokines and markers in fish species. 
For TNF-α and IL-1β the additions can be found in L95-99. Studies on the activities of 
IFN-α and Mx in teleosts were referenced in the original manuscript. Descriptions are 
now given in L100-106. Brief references to the existence and activity of CD8 in fish have 
also been made (L106-108), while reference to a very recent study on the expression and 
function of Eomesodermin in Atlantic salmon has been included in L108-111. 
 
Query 5: 
The authors should add the evidence-based descriptions that the early response (1-7 days 
post vaccination) of immune-related genes showed in the fig. 4 and 5 would be of benefit 
to DNA vaccination in the discussion part. 
Whereas some mention had been made to the benefit of these early responses, we 
agree that the original manuscript did not clarify the findings and evaluations of these in a 
satisfactory manner. The discussion has therefore to some extent been rewritten to clarify 
potential benefits as well as negative effects of the various early immune responses. 
The role of proinflammatory cytokines in the migration of inflammatory cells to the site 
of injection has been specified in the description of biological function (L95-97), whereas 
the potential influence of these cytokines on DNA vaccines and transgene expression is 
described in L434-442. Likewise, the antiviral functions of IFN-α and Mx and the 
relation to CD8 and Eomes expression can be found in the introduction, as described for 
query 4. In the discussion, L448-449 and L451-453 reference the importance of innate 
antiviral responses in teleosts and presents the potential benefit to later, acquired 
responses. In L455-457 a reference is given to the potential influence of PLGA particle 




Reviewer #2: I consider that author's answers for my comments were sufficient, and 
revisions made the manuscript clearer.  
 
The present study is now worthwhile publishing in Fish and shellfish immunology. 
 
However, there are two comments for the revised manuscript as shown in below. 
 
1. The authors used a term "vaccination" for pDNA delivery in the present study. Is this 
"vaccination" appropriate term for the experiment performed in the presents study? 
 
Response: We have changes the term “DNA vaccination” to “genetic engineering”  
 
2. For "Histopathology" in the section of results. The authors’ classified histological 
changes post injection. However, there is a low objectivity in this analysis. Therefore, the 
authors should make the all calcification index clear by showing all images of 
histological classification, if possible. 
I suppose that the result, "The histopathological changes caused by particles seemed to 
depend on particle size (nano vs. micro) rather than content (empty vs. pDNA)." is very 
important for the present study. Therefore, the authors should show detailed results for 
this analysis. 
 
Response: A calcification index is a measure of accumulation of calcium salts in a body 
tissue and thus not very relevant for this study, we think. However in certain cases, a 
calcification process may occur during inflammation and would preferably be observed 
and diagnostized by X-ray analysis. We have addressed the histopathological score vs. 
different particle sizes (table 4), but it is difficult to give exact quantitative score, as 
histological examination is a qualitative method. We are sorry that we cannot meet this 
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The use of poly-(D,L-lactic-co-glycolic) acid (PLGA) particles as carriers for DNA 25 
delivery has received considerable attention in mammalian studies. DNA vaccination of 26 
fish has been shown to elicit durable transgene expression, but no reports exist on 27 
intramuscular administration of PLGA-encapsulated plasmid DNA (pDNA). We injected 28 
Atlantic salmon (Salmo salar L.) intramuscularly with a plasmid vector containing a 29 
luciferase (Photinus pyralis) reporter gene as a) naked pDNA, b) encapsulated into 30 
PLGA nano- (~320nm) (NP) or microparticles (~4µm) (MP), c) in an oil-based 31 
formulation, or with empty particles of both sizes. The ability of the different pDNA-32 
treatments to induce transgene expression was analyzed through a 70-day experimental 33 
period. Anatomical distribution patterns and depot effects were determined by tracking 34 
isotope labeled pDNA. Muscle, head kidney and spleen from all treatment groups were 35 
analyzed for proinflammatory cytokines (TNFα, IL-1β), antiviral genes (IFN-α, Mx) and 36 
cytotoxic T-cell markers (CD8, Eomes) at mRNA transcription levels at days 1, 2, 4 and 37 
7. Histopathological examinations were performed on injection-site samples from days 2, 38 
7 and 30. Injection of either naked pDNA or the oil-formulation was superior to particle 39 
treatments for inducing transgene expression at early time-points. Empty particles of both 40 
sizes were able to induce proinflammatory immune responses as well as degenerative and 41 
inflammatory pathology at the injection site. Microparticles demonstrated injection-site 42 
depots and an inflammatory pathology comparable to the oil-based formulation. In 43 
comparison, the distribution of NP-encapsulated pDNA resembled that of naked pDNA, 44 
although encapsulation into NPs significantly elevated the expression of antiviral genes 45 
in all tissues. Together the results indicate that while naked pDNA is most efficient for 46 
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inducing transgene expression, the encapsulation of pDNA into NPs up-regulates 47 

























PLGA (poly-(D,L-lactic-co-glycolic)-acid) nano- and microparticles as adjuvants and 71 
carriers for vaccine antigens have been extensively investigated, mainly in mammalian 72 
models [1-5]. The biodegradable copolymer produces non-toxic degradation products [3], 73 
offers increased predictability of antigen release-rates, potential for intracellular antigen 74 
delivery and the ability to encapsulate and co-encapsulate a wide variety of antigens, 75 
including DNA vaccines [1, 6, 7]. 76 
Luciferase has commonly been applied for the evaluation of DNA vaccines at 77 
both transcription and protein level, and appears to express higher in fish than in 78 
mammals for a given dose of DNA [8-12]. The encapsulation of plasmid DNA into 79 
PLGA particles could protect against the rapid on-site degradation reported in both mice 80 
and salmon after intramuscular injection, and has been shown to increase the escape of 81 
antigen from endosomes to the cytosol [6, 8, 10, 11, 13].  82 
Depending on size, the particles may create injection-site depots (>5µm), get 83 
phagocytized by antigen presenting cells (APCs) (<5µm), be internalized by non-84 
phagocytic cells such as myocytes (<500nm) or escape into the bloodstream and 85 
subsequently be cleared by phagocytes in the head kidney, spleen and/or liver [4, 14]. 86 
Muscle cells have been shown to slowly accumulate pDNA over time, and could benefit 87 
from extracellular pDNA-releasing microparticles as well as intracellular nanoparticle 88 
depots [15]. 89 
A central attribute of DNA vaccines is the ability to induce cellular as well as 90 
humoral immune responses, including cytotoxic T-lymphocyte (CTL) responses and 91 
antibody production [16-18]. Unlike vertebrate DNA, bacterial DNA contains stretches of 92 
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unmethylated CpG sequences that are recognized as danger signals by toll-like receptor 9 93 
(TLR9). Upon stimulation this endosomal pattern recognition receptor (PRR) may induce 94 
a variety of cytokines. Interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) are 95 
hallmark cytokines in driving the inflammatory response in mammals and amongst other 96 
properties hold key roles in the migration of effector cells to sites of infection [19]. Both 97 
cytokines have been found in a number of teleost species and appear to exert functions 98 
similar to what is known from mammals [20-22].  99 
Interferon-α (IFN-α) is one of the type I IFNs, key mediators of antiviral 100 
responses through the regulation of IFN-stimulated genes and central in linking innate 101 
and adaptive immunity [16, 23-25]. The IFN-induced protein Mx has demonstrated 102 
antiviral functions in Atlantic salmon (Salmo salar L.) and can be used to follow IFN 103 
activity, as it has a much longer lifetime and accumulates to higher concentrations [26-104 
28]. Type I IFNs also play an important role in the clonal expansion and generation of 105 
specific as well as non-specific memory CD8
+
 T-cells [29]. Sequences for CD8α and 106 
CD8β are known from a variety of teleost species and the cytotoxic activity of CD8
+
 T-107 
cells has been demonstrated in rainbow trout (Oncorhynchus mykiss) [30, 31]. The 108 
transcription factor Eomesodermin (Eomes) is critical to the development of CD8
+
 T-cell 109 
effector functions and memory cells in mammals [32, 33]. A recent study indicated 110 
similar functions as well as induction by IFN-α in Atlantic salmon [34].  111 
Intramuscular injection of naked pDNA generally induces few and transient 112 
histopathological changes in fish as well as in mammals [9]. In contrast, the use of PLG 113 
microspheres as DNA carriers has been shown to result in a foreign body response in 114 
mice, where the infiltrating cells were also the ones that were primarily transfected [35]. 115 
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Enhanced inflammatory reactions coupled with prolonged availability of pDNA might 116 
therefore be beneficial to transgene expression and T-cell responses. 117 
This report is the first on intramuscular injection of Atlantic salmon with PLGA 118 
nano- and microparticles carrying pDNA, and the effect of these particles on 1) tissue 119 
distribution and retention of pDNA 2) expression of a firefly (Photinus pyralis) luciferase 120 
reporter gene 3) innate inflammatory (TNF-α, IL-1β) and antiviral (IFN-α, Mx) immune 121 
responses, 4) expression of cytotoxic T-cell markers (CD8, Eomes) and 5) injection site 122 
histopathology. We hypothesize that PLGA-encapsulated pDNA will induce transgene 123 
expression and proinflammatory as well as antiviral responses more efficiently than non-124 
encapsulated pDNA. 125 
 126 
 127 
2. Experimental 128 
2.1 Materials/Chemicals 129 
Poly(D,L-lactic-co-glycolic) acid (PLGA; 50:50 ratio, Mw of 7-17 kDa), poly vinyl 130 
alcohol (PVA, 87-89 % hydrolyzed), D-(+)-trehalose dehydrate, 1,3,4,6-tetrachloro-3α, 131 
6α-diphenylglycouril (Iodogen; Pierce, Rockford, IL, USA), Freund’s incomplete 132 
adjuvant (FIA)  and quantitative polymerase chain-reaction (QPCR) primers were 133 
purchased from Sigma Aldrich. Carrier free Na[
125
I] was from Perkin-Elmer Norge 134 
(Oslo, Norway). Acetone, dichloromethane (DCM) and chloroform were purchased from 135 
Merck Biochemicals. Sodium metabisulphite (Na2S2O5 > 98 % purity) and potassium 136 
iodide (KI > 99.5 % purity) were purchased from Fluka Biochemica. Luciferase 137 
lyophilizate was purchased from Roche Diagnostics GmbH (Mannheim, Germany).  138 
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2.2 Plasmid DNA 139 
Plasmid R70pRomiLuc (gift from Uwe Fischer, Friedrich-Loeffler-Institut, Germany) 140 
contains a firefly luciferase gene under the control of a murine cytomegalovirus 141 
immediate early promoter (CMV-IEP). The plasmid was isolated from a culture of 142 
Escherichia coli (strain DH5α) by use of Qiagen Plasmid Giga Kit (Qiagen GmbH, 143 
Hilden, Germany) according to manufacturer instructions. Purified plasmid was eluted in 144 
Tris-EDTA (TE) buffer (pH=8.0). DNA concentration and quality was determined with a 145 
NanoDrop® ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, 146 
USA) and 1% agarose gel-electrophoresis. High quality samples (A260/A280 ratio > 1.9 147 
and distinct DNA bands on gel) were stored at -20 ºC until use. 148 
 149 
2.3 Preparation of [
125
I]-fluorescein-pDNA 150 
Purified pDNA was modified using the nucleic acid labeling kit LabelIT Fluorescein 151 
(MIR 3200, Mirus Corp., Madison, WI, USA) according to manufacturer instructions. 152 
Radiolabeling of f-pDNA with carrier-free Na[
125
I] was performed in a direct reaction 153 
with 1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril as the oxidizing agent. The protocol 154 
was in accordance with the Iodogen method of radiolabeling [36], with minor 155 
modifications concerning incubation time (1h). Free iodine was removed by filtration on 156 
a PD-10 column equilibrated with pDNA in PBS. Radiation was determined by gamma 157 
counting (COBRA™ II Auto-Gamma®, ©Packard Instrument Co., Meridan, IL, USA), 158 









2.4 Preparation of naked and pDNA-loaded nano- and microparticles 162 
Particles were prepared by a modified version of the double emulsion (W1/O/W2) solvent 163 
evaporation method [2, 5, 37], outlined in table 1. A fraction of 
125
I-f-pDNA was 164 
included in the first water phase (W1) for determination of encapsulation efficiency and 165 
tracing of tissue distribution in in vivo experiments. Emulsions were prepared on ice-166 
baths by sonication (S) (Sonics VibraCell VC750, 3 mm tapered micro tip, Sonics & 167 
Materials Inc., Newtown, CT, USA) or homogenization (H) (Ultra-turrax® T-25 Basic, 168 
IKA®-WERKE, Staufen, Germany). Plasmid was excluded from the W1 phase for 169 
preparation of naked particles. Fifteen ml dH2O was added to the W1/O/W2-emulsions 170 
before overnight stirring to facilitate solvent evaporation. After centrifugation (Avanti® 171 
J-26 XP, BeckmanCoulter®, USA), pellets were re-suspended in dH2O and the fractions 172 
were pooled. Trehalose (5 mg ml
-1
 in dH2O) was used as a lyoprotectant and added to 173 
suspension aliquots in a ratio of 1:3. Aliquots were kept at -80˚C for a minimum of 2 h 174 
before lyophilization for 72 h at 0.001 hPa, -110 °C (ScanVac CoolSafe
TM
, LaboGene, 175 
Denmark). Lyophilizates were stored in airtight containers at 4 °C. 176 
 177 
2.5 Particle characterization 178 
Encapsulation of pDNA was determined by the gamma emission in a known amount of 179 
particles (COBRA™ II Auto-Gamma®) and measured radioactivity related to the 180 
specific radioactivity in the fraction of 
125
I-f-pDNA stock solution added to the W1-phase. 181 
Encapsulation efficiency was determined as entrapped amount of pDNA relative to the 182 
amount initially present in the W1-phase. Loading (µg pDNA mg
-1
 PLGA) was calculated 183 
by relating encapsulated pDNA to the total weight of retrieved particles. Sizing of 184 
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nanoparticles was performed by photon correlation spectroscopy (PCS) (NiComp 380 185 
Submicron Particle Sizer, Santa Barbara, USA). Microparticle size was determined by 186 
use of a Model 780 AccuSizer (NiComp). 187 
 188 
2.6 In vitro particle stability and pDNA release 189 
Five containers of 10 mg lyophilizate dissolved in 1 ml PBS (pH 7.4) with 0.02% sodium 190 
azide (NaN3) were prepared for both nano- and microparticles. The suspensions were 191 
incubated at 8˚C on a Stuart® SB3 rotator. Sampling was performed immediately after 192 
particles had been dissolved, and then at 3 h, day 1, 2, 4, 7, 14, 21, 30, 40, 50, 60 and 70. 193 
At each sampling 100 µl were removed and centrifuged at 15,000 x g for 1 minute. Fifty 194 
µl of the supernatant were removed for isotope measurement, and the remaining fraction 195 
transferred back to the original container after addition of 50 µl new PBS and full re-196 
suspension of the particle pellets. 197 
 198 
2.7 Fish 199 
Unvaccinated pre-smolt Atlantic salmon with a mean weight of 30 g were provided by 200 
and kept at Tromsø Aquaculture Research Station. The fish were kept in 200 L plastic 201 
tanks supplied with running fresh water (8-10˚C) and fed a commercial feed from 202 
Skretting AS (Stavanger, Norway). Adaptation to test conditions was performed for one 203 
week prior to immunization. All experiments were in compliance with The Norwegian 204 





2.8 Experimental groups and genetic engineering (GE) 208 
A total of 336 fish were distributed among seven tanks. Each tank contained 6 fish from 209 
each of the eight experimental groups (Table 2). Prior to tattooing and GE the fish were 210 
sedated with benzocaine using 40 mg L
-1
 (Benzoak Vet., ACD Pharmaceuticals, Leknes, 211 
Norway). The PanJet needle free injection system with saturated Alcian blue was used for 212 
tattooing. All formulations were administered in 50 µl volumes by injection in the left 213 
epaxial muscle. Each injection dose contained 11 µg pDNA, and the amount of NPs and 214 
MPs was adjusted to make up for differences in pDNA loading. Injection dose samples 215 
were collected from each formulation in order to determine cpm. 216 
 217 
2.9 Sampling 218 
The fish were starved for 24 h prior to sampling and killed by a double dose (80 mg L
-1
) 219 
of benzocaine. At day 1, 2, 4, 7, 14, 30 and 70 post injection one tank was sampled. All 220 
fish were weighed. Blood from fish given radioactive formulations was sampled using 221 
vacutainers (Becton Dickinson) and stored on ice. Two muscle samples from the 222 
injection site were transferred to 10% neutral buffered formalin for storage until 223 
histological processing. Muscle samples, spleens and head kidneys were transferred to 224 
separate tubes containing 1 ml RNAlater® (Ambion, Austin, TX, USA) and kept at room 225 
temperature overnight before storage at -20˚C. To determine tissue distribution in fish 226 
given radioactive formulations it was necessary to sample the full carcass. Trunk kidney, 227 
organ package (liver, heart, gastrointestinal tract (GIT) and interstitial adipose tissue), 228 
head (incl. gills) and remaining muscle (with skin) were collected in separate tubes. One 229 
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fish injected only with PBS was similarly sampled at each time point in order to exclude 230 
the possibility of radioactive contamination by cohabitation. 231 
 232 
2.10 Anatomic distribution and plasmid DNA retention 233 
Determination of in vivo retention and biodistribution was achieved by tracking trace 234 
amounts of 
125
I-f-pDNA. From blood samples, 50 µl were removed for analysis. 235 
Radioactivity in blood and trunk kidney samples was determined with a COBRA™ II 236 
gamma counter. Remaining samples, including spleen and injection site tissue, were 237 
analyzed using a Packard Auto-Gamma Scintillation Spectrometer (©Packard Instrument 238 
Co., model 5120). Background radiation was measured to be 50 and 100 cpm 239 
respectively for the two machines. These were set as baselines, and were subtracted from 240 
measured values before data were adjusted according to [
125
I] half-life. Blood volume 241 
was set to 4% of the body weight [38]. Mean values of the injection dose samples 242 
gathered during GE were used to determine total cpm recovery (%) at day 1. To 243 
determine the stability of retention, the daily cpm means were related to recovery at day 244 
1. Daily cpm means were used to determine anatomical distribution. 245 
 246 
 2.11 RNA isolation and cDNA synthesis 247 
Tissue samples (20-30 mg) were removed from RNAlater® and homogenized in lysis 248 
buffer from the RNeasy mini kit (Qiagen) using tubes with ceramic beads (Precellys) and 249 
a Precellys® 24 Homogenizer (Bertin Technologies). Parameters were set for 5300 x g x 250 
3 spins, 10 s. Subsequent RNA extractions and on-column purification with the RNase-251 
Free DNase Set from Qiagen were performed according to manufacturer instructions. 252 
12 
 
RNA was eluted in 50 µl RNase-free water and stored at -80˚C until use. RNA 253 
concentration and quality was determined using NanoDrop® (NanoDrop Technologies) 254 
and 1% agarose gel electrophoresis. High quality samples (260/280 ratio > 1.9 and tight 255 
18S/28S bands) were used for cDNA synthesis. Reverse transcription was performed 256 
with the High Capacity RNA-to-cDNA Master-mix from Applied Biosystems in 257 
accordance with manufacturer instructions. Each reaction contained 400 ng RNA in 20 258 
µl. Samples were diluted to 80 µl with RNase-free water and stored at -80˚C.  259 
 260 
2.12 Quantitative reverse transcription polymerase chain reaction (QPCR) 261 
Quantitative PCR was performed according to manufacturer instructions using Fast 262 
SYBR® Green Master Mix (Applied Biosystems) and primers previously applied in our 263 
laboratory (Table 3). Primer efficiency was determined using a six-point 1:2 dilution 264 
series in triplicate, with an initial cDNA concentration of 20 ng. All primers were free of 265 
primer-dimers in no-template control and showed a single peak in the dissociation curve. 266 
Samples containing 20 ng cDNA were run in triplicate, with each plate including no-267 
template control and an inter-run calibrator. Analysis was performed on a 7500 Fast Real-268 
Time PCR System (Applied Biosystems) with the thermal cycler profile set to 95˚C for 269 
20 s, 40 cycles of 95˚C for 3 s and 40 cycles of 60˚C for 30 s. Dissociation curves were 270 
performed on all samples. The 7500 Software Relative Quantification Study Application 271 
(v2.0.4, Applied Biosystems) was used to determine CT values, with walking baseline 272 
and threshold set manually to be equal for all genes. Relative gene expression was 273 
determined by the Pfaffl method [39], comparing saline injected fish to treated groups. 274 
To determine relative expression of luciferase the highest day 1 transcript average was 275 
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used as control. Head kidney and spleen samples from day 2 and 7 were also checked for 276 
luciferase transcripts. 277 
 278 
2.13 Histology 279 
Muscle samples from days 2, 7 and 30 post injection were chosen for histology. The 280 
service of routine histological processing and staining with hematoxylin and eosin (HE) 281 
was purchased from the National Veterinary Institute (Oslo, Norway). Sections were 282 
studied by light microscopy for signs of hemorrhages, tissue degradation and 283 
inflammation. Using the changes in day 2 saline injected fish as a baseline, observed 284 
changes were classified as either moderate (+) or strong (++). Moderate changes were 285 
determined as largely limited to the needle trajectory, with inflammatory cells primarily 286 
associated with degenerated tissue and/or dispersed among intact muscle cells. Strong 287 
changes were seen as degeneration and/or inflammation spreading beyond the needle 288 
trajectory, with few or no intact muscle cells present within the cellular infiltrate. The 289 
histopathology scores were performed as blind testing by two professionals. 290 
  291 
2.14 Statistical analysis 292 
Microsoft Excel (Microsoft™) was used for arrangement of data as well as calculation of 293 
biodistribution and relative gene expression. Statistical analyses for real-time PCR were 294 
performed with IBM SPSS (Statistical Package for the Social Sciences, version 19.0). All 295 
data were natural log transformed prior to analysis, and normality verified by the 296 
Shapiro-Wilk test. Levene’s test of equality of variances was used to check for 297 
homoscedasticity. Homoscedastic data were analyzed by one-way ANOVA with Tukey 298 
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as the post hoc test. Where homoscedasticity was violated, the Welch test of equality of 299 
means was applied, followed by Dunnett T3 post hoc. Graphs were constructed with 300 
Microsoft Excel and SPSS. 301 
 302 
 303 
3. Results 304 
3.1 Particle characterization 305 
The encapsulation efficiency and loading of 
125
I-f-pDNA were low for both particles 306 
sizes. The different particle characteristics are summarized in table 1, where empty 307 
particles have been excluded due to minor size differences. The mean size of 308 
nanoparticles was 320 nm by intensity distribution, with more than 90% measuring less 309 
than 500 nm. The number weight mean diameter of microparticles was 3-4 µm, with 80% 310 
measuring less than 5 µm and more than 90% smaller than 10 µm.  311 
 312 
3.2 In vitro particle stability and pDNA release 313 
Neutral pH and a temperature of 8˚C were chosen in order to simulate in vivo conditions. 314 
Initial burst release was 81% for NP-(
125
I-f-pDNA) and 49% for MP-(
125
I-f-pDNA). Both 315 
groups subsequently displayed a slow and sustained release, with a 96% and 69 % 316 
accumulated release at day 70 (Fig. 1). 317 
 318 
3.3 Anatomical distribution and depot of vaccine formulations 319 
No radioactivity was registered in blood later than day 7-post injection. The average total 320 
cpm recovery at day 1 ranged from 15% for NP-(
125





(results not shown). Radioactivity was primarily recovered from the injection site, organs 322 





I-f-pDNA (Fig. 2A, B). Likewise, MP-(
125
I-f-pDNA) and FIA-324 
(
125
I-f-pDNA) had similar distribution profiles and injection site depots (Fig. 2C, D). The 325 





containing almost 80% of total radiation at day 70. NP-(
125
I-f-pDNA) showed higher 327 
injection site retention (5%) at day 70 compared to 
125





I-f-pDNA) were 34% and 26%, with retention 329 
in trunk kidney reaching 32% and 27% at day 70.  330 
 331 
3.4 Quantitative reverse transcription polymerase chain reaction (QPCR) 332 
3.4.1 Expression of luciferase reporter gene 333 
FIA-(
125
I-f-pDNA) induced the highest luciferase transcript average in muscle at day 1 334 
and was chosen as calibrator for this tissue. FIA-(
125
I-f-pDNA) also induced the highest 335 
individual levels of luciferase transcripts throughout the experiment, with significant 336 
expression at day 1, 4 and 14 (p ≤ 0.032) (Fig. 3). Naked plasmids consistently induced 337 
higher expression than the particle formulations, with significance for pDNA at day 1-7 338 
(p ≤ 0.042) and 
125
I-f-pDNA at day 4 (p = 0.018). No significant differences were found 339 
at days 30 and 70. Low luciferase transcript levels were detected in head kidney, with 340 
pDNA and 
125
I-f-pDNA inducing significant expression compared to NP-
125
I-f-pDNA at 341 





3.4.2 Proinflammatory cytokines IL-1β and TNF-α 345 
The particle formulations significantly up-regulated IL-1β in muscle samples at all time-346 
points; NP-(
125
I-f-pDNA) (p ≤ 0.002), NP (p ≤ 0.004), MP-(
125
I-f-pDNA) (p ≤ 0.003), 347 
MP (p ≤ 0.015) (Fig. 4A). From day 2 the up-regulation was significant compared to all 348 
non-particle groups. MP formulations consistently induced the highest expression. FIA-349 
(
125
I-f-pDNA) significantly up-regulated IL-1β in muscle at day 7 (p = 0.000). Significant 350 
expression of TNF-α in head kidney was only found at day 4, with NP-(
125
I-f-pDNA) (p 351 
= 0.034) and MP (p = 0.008) (Fig. 4B). No significant expression of TNF-α was found in 352 
the spleen or muscle. 353 
 354 
3.4.3 IFN-α and Mx 355 
NP-(
125
I-f-pDNA) significantly up-regulated IFN-α at the injection site at day 4 (p = 356 
0.005). Levels in head kidney were generally low, with significant up-regulation by 
125
I-357 
f-pDNA (p = 0.000) at day 2. NP-(
125
I-f-pDNA) (p ≤ 0.003) and NP (p ≤ 0.036) 358 
significantly up-regulated IFN-α in spleen at day 1 and 2 (results not shown). Levels of 359 
Mx at the injection site increased for all groups from day 1 to 7. NP-(
125
I-f-pDNA) 360 
induced significant expression at day 2-7 (p = 0.000), and was superior to all groups at 361 
day 4 and 7 (p ≤ 0.020). MP-(
125
I-f-pDNA) significantly up-regulated Mx in muscle at 362 
day 2 and 4 (p ≤ 0.006) (Fig. 5A). NP-(
125
I-f-pDNA) appeared the most potent treatment 363 
for inducing Mx in head kidney, but no significance was found (Fig. 5B). Mx expression 364 
increased in spleen for all groups from day 1 to 7, with significance for NP-(
125
I-f-pDNA) 365 




3.4.4 CD8 and Eomes 368 
There was no significant up-regulation of CD8 in any tissue. Several muscle samples 369 
showed no CD8 expression, and no statistical analyses could therefore be performed. 370 
No expression of CD8 could be detected at day 2 in head kidney samples from fish 371 
injected with 
125
I-f-pDNA. Interestingly, these samples induced the only significant up-372 
regulation of Eomes observed within any tissue (p = 0.000) (results not shown). 373 
 374 
3.6 Histopathology 375 
Tissue sections of injection site samples were examined by light microscopy for signs of 376 
hemorrhages, muscle degeneration and inflammation (Table 4). PBS caused only minor 377 
hemorrhages and tissue degeneration at day 2 (Fig. 6A), indicating that later changes 378 
were likely the results of the different treatments. Hemorrhages were most pronounced at 379 
day 2 in all groups. Administration of PBS and 
125
I-f-pDNA caused moderate muscle 380 
degeneration, but no inflammation. Both tissue degeneration and inflammation were 381 





I-f-pDNA) both demonstrated strong 383 
inflammation at day 30 (Fig. 6B, D), with a high influx of inflammatory cells that for 384 
FIA-(
125
I-f-pDNA) was concentrated around possible oil-droplets. The histopathological 385 
changes caused by particles seemed to depend on particle size (nano vs. micro) rather 386 






4. Discussion 391 
The use of PLGA particle constructs as carriers for DNA vaccine delivery has so far 392 
received little attention in fish studies [1, 40]. We have investigated distribution/depot, 393 
transgene and immune gene transcription as well as injection site histopathology 394 
following intramuscular injection of Atlantic salmon with PLGA particles carrying 395 
pDNA-encoding luciferase. The double emulsion solvent evaporation method [2, 37] was 396 
used to prepare nano- and microparticles with mean diameters of 320 nm and 4 µm, 397 
respectively. Low pDNA encapsulation appears to be a recurring problem, and our results 398 
(<30% for both particle sizes) are supported by other studies [12, 35]. 399 
One of the challenges of conventional DNA vaccination is the rapid tissue 400 
clearance and on-site degradation of DNA, which may result in reduced pDNA uptake 401 
and transgene expression [8, 10]. Although oil adjuvants are not commonly applied for 402 
intramuscular vaccine delivery, FIA-(
125
I-f-pDNA) provided a positive control to 403 
measure the depot potential of nano- and microparticles. The high burst release observed 404 
for NP-(
125
I-f-pDNA) during the in vitro release study (Fig. 1) likely explains the strong 405 
similarities between this group and 
125
I-f-pDNA (Fig. 2A, B), a similarity reflected also 406 
in the injection site histopathology (Table 4). In comparison, the injection site retention 407 
of MP-(
125
I-f-pDNA) remained similar to that of FIA-(
125
I-f-pDNA) throughout the study 408 




I-f-pDNA) depots likely 409 
contributed to the severe histopathological inflammations observed in tissue sections 410 
from both groups at day 30 (Fig. 6B, D). Inflammatory cell infiltration has been shown to 411 
take place in both fish and mammals [35, 37, 41], and transient inflammatory responses 412 
may thus contribute to increased transgene expression. Long lasting inflammations such 413 
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I-f-pDNA) are, however, undesirable in a 414 
product meant for consumption. It would appear that nanoparticles may be favorable in 415 
order to avoid potential tissue damage, but the small sample sizes meant we could only 416 
obtain an indication of the histopathological influence of the various treatments. 417 
Although the similarities in injection site retention were not reflected in the 418 
expression of the luciferase transgene (Fig. 3), the observation that FIA-(
125
I-f-pDNA) 419 
induced the highest individual levels of luciferase transcripts suggests that increased 420 
cellular infiltration along with a high injection site pDNA depot may be of benefit to 421 
transgene expression in Atlantic salmon. The significantly lower expression obtained 422 
with encapsulated pDNA could be a result of the preparation conditions, as the W1/O/W2 423 
method has been shown to cause a partial reduction in the content of supercoiled (SC) 424 
DNA topoform that contributes to a lower transfection efficiency [1, 8, 37, 42]. The 425 
process of emulsification required lower shear forces and shorter duration of preparation 426 
and may thus have preserved a larger portion of SC DNA in FIA-(
125
I-f-pDNA). We did 427 
not, however, address whether the encapsulation of 
125
I-f-pDNA resulted in an altered SC 428 
content. The absence of significant differences in luciferase expression at day 30 and 70 429 
still indicated a certain level of stability in particle groups that could result from a 430 
continued release of bioactive pDNA even at later time-points. 431 
Another explanation for the low transcription levels obtained with encapsulated 432 
pDNA-Luc may lie with the inflammatory cytokine responses. Induced not only by 433 
stimulation of PRRs but also by PLGA itself [43, 44], IL-1β and TNF-α have both 434 
demonstrated inhibitory effects on transgene expression even at low concentrations, 435 
contributing to a reduced transfection efficiency of encapsulated DNA in vivo as opposed 436 
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to in vitro [2, 37, 45]. The nano- and microparticle formulations significantly up-437 
regulated IL-1β at the injection site at all time-points (Fig. 4A), and while the expression 438 
of TNF-α was generally low a synergistic effect of different cytokines on the inhibition of 439 
transgene expression has been reported [45]. In comparison, the levels of IL-1β in fish 440 
injected with FIA-(
125
I-f-pDNA) were not found significant until 7 days post 441 
administration, indicating that PLGA may provide a more potent inflammatory stimulus 442 
than the oil adjuvant even in the absence of pronounced inflammatory histopathology. 443 
Viral challenge studies in fish have shown that specific protection may be 444 
acquired even with very low doses of DNA, and innate antiviral responses also appear to 445 
play a more critical role in fish than mammals upon exposure to viruses [46, 47]. 446 
Whereas luciferase is unlikely to induce a differentiation of antigen specific CD8
+
 T-cells 447 
due to low immunogenicity in in vivo studies [48, 49], type I IFNs play an important role 448 
in the clonal expansion of CD8
+
 T-cells and may enhance CTL responses when 449 
immunogenic transgene products are expressed [29]. Whereas the expression of IFN-α 450 
was generally low and transient, NP-(
125
I-f-pDNA) still appeared the most potent inducer 451 
of antiviral responses and significantly up-regulated the expression of Mx in all tissues 452 
(Fig. 5). This result supports a previous study on the influence of particle size on the 453 
cytokine profile induced after administration of particle associated CpG DNA [50]. We 454 
did observe that formulations with naked pDNA significantly up-regulated both Eomes 455 
and IFN-α in head kidney at day 2, but no statistical correlation between these genes was 456 
found for any other group, tissue or time-point. 457 
This study is the first on intramuscular injection of Atlantic salmon with PLGA 458 
particles carrying pDNA. Our particle formulations did not induce transgene expression 459 
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as efficiently as injection of naked plasmids, but appeared to provide a continued release 460 
of bioactive pDNA even at the end of the study. A strong expression of transgene may 461 
not always be necessary in order to mount a significantly protective immune response, 462 
and an efficient up-regulation of innate antiviral responses in particular might enhance 463 
the immunogenicity of an antiviral vaccine. Both particle sizes proved superior to naked 464 
pDNA injection for the induction of IL-1β as well as an influx of inflammatory cells at 465 
the injection site, but only encapsulation into nanoparticles significantly increased the 466 
expression of IFN-α and Mx. Together these results indicate that PLGA nanoparticles as 467 
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Figure 1 - Release of 125I-f-pDNA from nano- and microparticles through 70 days of incubation at 8˚ C, presented as the mean 
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Figure 2 – Radioactivity recovered from samples of trunk kidney (TK), organs (Org) and injection site (I.S.). The stacked bars 
represent the relative distribution of pDNA among these organs in groups A) NP-(125I-f-pDNA), B) 125I-f-pDNA, C) MP-(125I-f-
























Figure 3 - Relative expression of luciferase mRNA transcripts in muscle from the injection site through the 70 day sample 
period. The box-plot shows the median value (line) and maximum and minimum values (whiskers), with the box representing 
50% of the samples. Circles show outliers. The highest cpm-average at day 1 was found in group FIA-(125I-f-pDNA) and was 














































Figure 4 – Relative expression of proinflammatory cytokines; A) IL-1β in muscle from the injection site and B) TNF-α in head 
kidney. The box-plot shows the median value (line) and maximum and minimum values (whiskers), with the box representing 

























































Figure 5 - Expression of the antiviral protein Mx in A) injection site muscle, B) head kidney and C) spleen. The box-plots show 
median values (line) and maximum and minimum values (whiskers), with the boxes representing 50% of the samples. Circles 


























Figure 6 – All pictures show transversal sections of skeletal muscle from the injection site, stained with hematoxylin and eosin 
(HE). A) Minor hemorrhages (arrow) and muscle cell degeneration in negative control (PBS) group observed at day 2.  B) 
Massive cellular infiltrate in the myocyte fibre and surrounding interstitium at day 30 in tissue of fish injected with MP-(125I-f-
pDNA). Magnification of cellular infiltrate is shown with a 10.0 µm scale-bar. C) Focal muscle cell degeneration (star) and 
minor hemorrhages (arrows) can be seen at day 7 in samples from fish injected with pDNA.  D) Large oil-droplets 
(arrowheads) surrounded by degenerative muscle fibers and inflammatory cells at day 30 after injection of FIA-(125I-f-pDNA). 
 
  




Table 1 – An overview of the preparation protocol and main particle characteristics for pDNA-loaded PLGA nanoparticles 
(NP-(125I-f-pDNA)) and microparticles (MP-(125I-f-pDNA)). (S): preparation by sonication. (H): preparation by 
homogenization. Preparation of empty particles followed the same protocol, but pDNA was excluded from the W1 phase. 
 NP-(125I-f-pDNA) MP-(125I-f-pDNA) 
First water phase (W1) pDNA (3.5 mg) in 600 µl dH2O with 0.1% PVA 
Oil phase (O) 
300 mg PLGA in 6 ml chloroform  
(5% w/v) 
First emulsion (W1/O) S: 30 sec, 35% (262.5 W) S: 35 sec, 30% (225 W) 
Second water phase (W2) 15 ml dH2O with 2% PVA 
Second emulsion (O/W2) S: 1 min, 30% H: 45 sec, 9500 rpm min
-1 
Washing 5000 x g, 15000 x g and 25000 x g 500 x g 
Particle yield (%) 78 89 
Encapsulation efficiency (%) 27 24 
Loading  
(µg pDNA/mg PLGA) 
3.24 2.85 
Mean size 320 nm 3-4 µm 
PLGA injected (mg) 3.5 4 
 
 
Table 2 - Experimental groups and group nomenclature.  
Treatment groups Nomenclature 
(125I-f-pDNA) encapsulated in nanoparticles NP-(125I-f-pDNA) 
(125I-f-pDNA) encapsulated in microparticles MP-(125I-f-pDNA) 
Empty nanoparticles NP 
Empty microparticles MP 
Plasmid DNA in PBS pDNA 
(125I-f-pDNA) in PBS 125I-f-pDNA 
PBS PBS 






Table 3 - Primers for quantitative polymerase chain reaction (QPCR). (*): primers obtained from Natasha Hynes (TNF-α) and 
Jaya Kumari (Eomes). 









































































Table 4 - Histopathological observations in tissue-sections of muscle from the injection site. Muscle degeneration and 
inflammation are classified as either moderate (+) or strong (++), depending on the extent of the pathology. 
Sampling Group Total number of fish Hemorrhage 
Muscle degeneration Inflammation 
+ ++ + ++ 
D2 
NP-(125I-f-pDNA) 3 2 2 0 0 0 
MP-(125I-f-pDNA) 3 2 3 0 2 0 
NP 2 1 1 1 0 0 
MP 3 2 0 2 0 0 
pDNA 3 1 1 2 0 0 
125I-f-pDNA 3 2 0 0 0 0 
PBS 2 1 2 0 0 0 
FIA-(125I-f-pDNA) 1 - 1 - - - 
D7 
NP-(125I-f-pDNA) 3 2 2 0 2 0 
MP-(125I-f-pDNA) 3 0 3 0 2 0 
NP 2 0 1 1 2 0 
MP 2 1 2 0 2 0 
pDNA 3 1 2 0 1 0 
125I-f-pDNA 3 2 1 0 0 0 
PBS 2 0 0 0 0 0 
FIA-(125I-f-pDNA) 1 - - - - - 
D30 
NP-(125I-f-pDNA) 2 0 0 0 2 0 
MP-(125I-f-pDNA) 2 0 1 1 0 2 
pDNA 2 0 0 0 2 0 
125I-f-pDNA 2 0 0 0 0 0 
PBS 1 0 0 0 0 0 
FIA-(125I-f-pDNA) 1 - - - - 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
